194 related articles for article (PubMed ID: 12096664)
21. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
Tsuboi K; Yamamoto H
Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22498845
[TBL] [Abstract][Full Text] [Related]
22. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
Kisinovsky I; Cáceres G; Coronel C; Reisin R
Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
Desnick RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
[TBL] [Abstract][Full Text] [Related]
24. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
Tsuboi K; Yamamoto H
Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22878505
[TBL] [Abstract][Full Text] [Related]
25. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB
J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
[TBL] [Abstract][Full Text] [Related]
27. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
Wanner C
Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
[No Abstract] [Full Text] [Related]
28. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
29. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.
Hajioff D; Enever Y; Quiney R; Zuckerman J; Mackermot K; Mehta A
J Inherit Metab Dis; 2003; 26(8):787-94. PubMed ID: 14739683
[TBL] [Abstract][Full Text] [Related]
30. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
[TBL] [Abstract][Full Text] [Related]
31. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
Lenders M; Brand E
J Med Genet; 2024 May; 61(6):531-533. PubMed ID: 38538083
[No Abstract] [Full Text] [Related]
32. Fabry disease: a treatable lysosomal storage disorder.
Phadke SR; Mandal K; Girisha KM
Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
[TBL] [Abstract][Full Text] [Related]
33. Fabry disease in children and the effects of enzyme replacement treatment.
Pintos-Morell G; Beck M
Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
[TBL] [Abstract][Full Text] [Related]
34. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion.
Guest JF; Jenssen T; Houge G; Aaseboe W; Tøndel C; Svarstad E
Eur J Clin Invest; 2010 Dec; 40(12):1104-12. PubMed ID: 21070219
[TBL] [Abstract][Full Text] [Related]
35. Agalsidase Beta: a review of its use in the management of Fabry disease.
Keating GM; Simpson D
Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
[TBL] [Abstract][Full Text] [Related]
36. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage.
Riccio E; Pisani A
Clin Genet; 2023 Mar; 103(3):371-376. PubMed ID: 36373246
[TBL] [Abstract][Full Text] [Related]
37. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
Warnock DG; Wallace EL
J Med Genet; 2024 May; 61(6):534-535. PubMed ID: 38589225
[No Abstract] [Full Text] [Related]
38. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
39. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
40. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]